Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues.

about

Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues.

Item

http://www.wikidata.org/entity/Q39280587

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Preclinical rationale for syne ...... ytotoxic nucleoside analogues.

@en

Preclinical rationale for syne ...... ytotoxic nucleoside analogues.

@nl

type

Item

label

Preclinical rationale for syne ...... ytotoxic nucleoside analogues.

@en

Preclinical rationale for syne ...... ytotoxic nucleoside analogues.

@nl

prefLabel

Preclinical rationale for syne ...... ytotoxic nucleoside analogues.

@en

Preclinical rationale for syne ...... ytotoxic nucleoside analogues.

@nl

P1476

Preclinical rationale for syne ...... ytotoxic nucleoside analogues.

@en

P2093

Daishi Kasai

http://www.w3.org/2001/XMLSchema#string

Eiji Kunii

http://www.w3.org/2001/XMLSchema#string

Hiroaki Ozasa

http://www.w3.org/2001/XMLSchema#string

Hirotsugu Ohkubo

http://www.w3.org/2001/XMLSchema#string

Ken Maeno

http://www.w3.org/2001/XMLSchema#string

Mikinori Miyazaki

http://www.w3.org/2001/XMLSchema#string

Osamu Takakuwa

http://www.w3.org/2001/XMLSchema#string

Shigeki Sato

http://www.w3.org/2001/XMLSchema#string

Takehiro Uemura

http://www.w3.org/2001/XMLSchema#string

Tetsuya Oguri

http://www.w3.org/2001/XMLSchema#string

P2860

Nucleoside analogues and nucleobases in cancer treatment.

FDA drug approval summaries: pemetrexed (Alimta).

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.

Drug therapy for acute myeloid leukemia.

ABCC11/MRP8 confers pemetrexed resistance in lung cancer.

Significance of thymidylate synthase for resistance to pemetrexed in lung cancer.

The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.

P304

571-575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2012.773

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230834457

http://www.w3.org/2001/XMLSchema#string

P698

22970056

http://www.w3.org/2001/XMLSchema#string

P932

3439182

http://www.w3.org/2001/XMLSchema#string